局部枸橼酸抗凝在接受连续性肾脏替代治疗的肝病合并急性肾损伤中的应用效果观察

宁琪琪; 高原; 段美丽; 刘海霞; 孟庆华; 于红卫; 胡中杰; 朱跃科

doi:10.3969/j.issn.1001-5256.2020.05.021

局部枸橼酸抗凝在接受连续性肾脏替代治疗的肝病合并急性肾损伤中的应用效果观察

DOI: 10.3969/j.issn.1001-5256.2020.05.021

1. 首都医科大学附属北京佑安医院肝病重症医学科
2. 首都医科大学附属北京友谊医院重症医学科

基金项目:

国家科技重大专项（2018ZX10302-206-003-007）；北京市丰台区卫生计生系统科学研究项目（2017-60）；

详细信息

中图分类号: R575;R692
计量
- 文章访问数: 1199
- HTML全文浏览量: 83
- PDF下载量: 136
- 被引次数: 21
出版历程
- 出版日期: 2020-05-20

Efficacy and safety of regional citrate anticoagulation in patients with severe liver diseases and acute kidney injury receiving continuals renal replacement therapy

Department of Severe Liver Disease, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

摘要

摘要:
目的探讨在接受连续性肾脏替代治疗（CRRT）的严重肝病合并急性肾损伤（AKI）患者中应用滤器局部枸橼酸抗凝（RCA）的有效性及安全性。方法回顾性收集2016年1月-2019年3月于首都医科大学附属北京佑安医院和首都医科大学附属北京友谊医院行RCA-CRRT的175例肝病合并AKI患者（肝病组）和285例非肝病合并AKI患者（非肝病组）的住院病历资料以及首次CRRT记录资料。观察并比较患者治疗前后肝肾功能生化指标、血气分析、乳酸、钙离子(iCa2+)和总钙(tCa2+)的变化、滤器平均运行寿命、不良反应等。符合正态分布的计量资料组内比较采用配对t检验,两组间比较采用独立样本t检验;不符合正态分布的计量资料两组间比较采用Mann-WhitneyU检验。计数资料两组间比较采用χ2检验。采用Kaplan-Meier生存曲线分析两组间的滤器运行寿命并应用log-rank检验进行比较。结果 CRRT前,肝病组患者ALT、AST、TBil、BUN水平均显著高于非肝病组（P值均<0. 05）。肝病组和非肝病组患者经治疗后,iCa<...
- 肝疾病 /
- 急性肾损伤 /
- 肾替代疗法 /
- 柠檬酸盐类
Abstract:
Objective To investigate the efficacy and safety of regional citrate anticoagulation(RCA) in patients with severe liver diseasesand acute kidney injury(AKI) receiving continuous renal replacement therapy(CRRT).Methods A retrospective analysis was performedfor the medical records and first-time CRRT data of 175 liver disease patients with AKI(liver disease group) and 285 non-liver diseasepatients with AKI(non-liver disease group) who underwent RCA-CRRT in Beijing You' an Hospital and Beijing Friendship Hospital,Capital Medical University, from January 2016 to March 2019. The two groups were compared in terms of the changes in hepatic and renalfunction markers, blood gas parameters, lactic acid, ionized calcium(iCa2+), and total calcium(tCa2+) after treatment, as well as themean operation life of filter and adverse reactions. The pairedt-test or the independent samplest-test was used for comparison of normallydistributed continuous data between two groups, and the Mann-WhitneyUtest was used for comparison of non-normally distributed contin-uous data between two groups; the chi-square test was used for comparison of categorical data between two groups. The Kaplan-Meier sur-vival curve was used to analyze the operation life of filter in the two groups, and the log-rank test was used for comparison.Results BeforeCRRT, the level of ALT、AST、TBil、BUN in liver disease group were significantly higher than those in non-liver disease group(allP<0. 05). After treatment, iCa2+, tCa2+, pH value, and base excess basically returned to normal, and there were significant differences inthe same group before and after treatment(allP< 0. 05). Compared with the non-liver disease group, the liver disease group had a signifi-cantly higher incidence rate of citrate accumulation(tCa2+/iCa2+>2. 5) during treatment(12% vs 2. 2%,χ2 =18.65,P< 0. 001).There was no significant difference in the mean operation life of filter between the liver disease group and the non-liver disease group(32. 20 ± 24. 99 h vs 32. 96 ± 18. 93 h,t =0.346,P> 0. 05) and there was also no significant difference in the 48-hour survival rate withfilter between the two groups(28. 1% vs 26. 9%,χ2 =1.356,P= 0. 381). No adverse reaction associated with citrate accumulation wasobserved.Conclusion In patients with severe liver diseases, although RCA used in CRRT may induce a high incidence rate of citrate accu-mulation, it can achieve a satisfactory anticoagulant effect and is relatively safe.
- liver diseases /
- acute kidney injury /
- renal replacement therapy /
- citrates

HTML全文

参考文献(17)

[1] DAVENPORT A, SHEIKH MF, LAMB E, et al. Acute kidney injury in acute-on-chronic liver failure:Where does hepatorenal syndrome fit?[J]. Kidney Int, 2017, 92(5):1058-1070.

[2] ZHAI XR, XU X, CHEN J, et al. Effect of response at 48 hours of treatment of acute kidney injury on short-term prognosis of hepatitis B virus-associated acute-on-chronic liver failure[J]. J Clin Hepatol, 2019, 35(9):2001-2005.(in Chinese）翟兴冉，许祥，陈婧，等．急性肾损伤治疗48小时应答与否对HBV相关慢加急性肝衰竭短期预后的影响[J]．临床肝胆病杂志，2019, 35(9):2001-2005.

[3] XU MM, CHEN Y. Predictive factors for acute kidney injury in patients with liver cirrhosis[J]. J Clin Hepatol, 2018, 34(10):2124-2129.(in Chinese）徐曼曼，陈煜．肝硬化合并急性肾损伤的尿液相关预测因素分析[J]．临床肝胆病杂志，2018, 34(10):2124-2129.

[4] CHENG XS, TAN JC, KIM WR. Management of renal failure in end-stage liver disease:A critical appraisal[J]. Liver Transpl, 2016, 22(12):1710-1719.

[5] ANGELI P, GINES P, WONG F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis:Revised consensus recommendations of the International Club of Ascites[J]. Gut, 2015, 64(4):531-537.

[6] WU MY, HSU YH, BAI CH, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy:A meta-analysis of randomized controlled trials[J]. Am J Kidney Dis, 2012, 59(6):810-818.

[7] WEI XH, YE GL, LIU WY, et al. Clinical application of regional citrate anticoagulation in continuous renal replacement therapy after cardiopulmonary bypass[J]. Traum Crit Med, 2018, 6(1):48-50.(in Chinese）魏晓华，叶光磊，刘文悦，等．局部枸橼酸抗凝在体外循环术后患者连续性肾替代治疗中临床应用[J]．创伤与急危重病医学，2018, 6(1):48-50.

[8] SCHULTHEIβC, SAUGEL B, PHILLIP V, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure:A prospective observational study[J]. Crit Care, 2012, 16(4):r162.

[9] COINTAULT O, KAMAR N, BORIES P, et al. Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions[J]. Nephrol Dial Transplant, 2004,19(1):171-178.

[10] LINK A, KLINGELE M, SPEER T, et al. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients[J].Crit Care, 2012, 16(3):r97.

[11] APSNER R, SCHWARZENHOFER M, DERFLER K, et al. Impairment of citrate metabolism in acute hepatic failure[J].Wien Klin Wochenschr, 1997, 109(4):123-127.

[12] KHADZHYNOV D, SCHELTER C, LIEKER I, et al. Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation[J]. J Crit Care, 2014, 29(2):265-271.

[13] MEHTA RL, McDONALD BR, WARD DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis. An update after 12 months[J]. Contrib Nephrol, 1991, 93:210-214.

[14] SLOWINSKI T, MORGERA S, JOANNIDIS M, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure:The Liver Citrate Anticoagulation Threshold(L-CAT)observational study[J]. Crit Care, 2015, 19:349.

[15] KALEMBA KM, WANG Y, XU H, et al. Glycerol induces G6pc in primary mouse hepatocytes and is the preferred substrate for gluconeogenesis both in vitro and in vivo[J]. J Biol Chem,2019, 294(48):18017-18028.

[16] AGARWAL B, SHAW S, SHANKAR HARI M, et al. Continuous renal replacement therapy(CRRT)in patients with liver disease:Is circuit life different?[J]. J Hepatol, 2009, 51(3):504-509.

[17] WANG W, CHANG P, LIU ZG, et al. Regional citrate anticoagulation in critical patients with liver dysfunction[J]. Chin J Crit Care Med, 2016, 36(1):52-55.(in Chinese）王伟，常平，刘占国，等．局部枸橼酸抗凝在重症患者肝功能异常中的应用[J]．中国急救医学，2016, 36(1):52-55.

施引文献

期刊类型引用(20)

1.	朱宏坤，戴芳芳，钱世宁. 血必净注射液对行连续性肾脏替代疗法的多器官功能障碍综合征患者凝血功能的影响. 哈尔滨医科大学学报. 2024(01): 75-79 . 百度学术
2.	肖晶晶. 局部枸橼酸抗凝联合CRRT治疗脓毒症合并急性肾衰竭的临床疗效及对患者凝血功能的影响. 延边大学医学学报. 2024(05): 534-537 . 百度学术
3.	王娟，张丽萍，丁童，卫淑润，翁志华. 局部枸橼酸抗凝血液净化技术在ICU造血干细胞移植后弥漫性肺泡出血患者治疗中应用价值. 临床军医杂志. 2023(05): 522-524 . 百度学术
4.	孙卫和，许伟伟，冒秀宏，汪涛. 局部枸橼酸抗凝在重症急性肾损伤患者连续性肾脏替代治疗中的应用. 中外医疗. 2023(18): 129-132 . 百度学术
5.	赵志强，孟鹏飞，石正松，陈亚君，肖宏涛. 枸橼酸抗凝在脓毒症伴高危出血行连续性肾脏替代治疗患者中的应用效果. 医药论坛杂志. 2023(19): 14-18 . 百度学术
6.	李一青，白银果，沙莎. 连续性静脉-静脉血液滤过透析和局部枸橼酸抗凝在重症患者乳酸升高时应用的有效性和安全性研究. 贵州医药. 2023(11): 1704-1705 . 百度学术
7.	张妍，荣阳，张芳. CRRT治疗肾衰竭合并顽固性心力衰竭的临床效果. 中西医结合心脑血管病杂志. 2022(02): 285-288 . 百度学术
8.	张竞葳，田敏，余建斌. 局部枸橼酸抗凝应用于维持性血液透析合并消化道出血患者的疗效观察. 现代医学与健康研究电子杂志. 2022(13): 130-134 . 百度学术
9.	陈伟玲，邓虹，黄颖妍，李乐，张洪举. 局部枸橼酸抗凝在连续性肾替代疗法治疗中的效果及安全性指标的变化. 北方药学. 2022(05): 116-119 . 百度学术
10.	吴允东，江海娇，张伟，曹迎亚，杨尚志，周伟. 不同抗凝方案用于心脏术后患者连续性肾脏替代治疗中的效果. 皖南医学院学报. 2022(05): 436-439+443 . 百度学术
11.	严海燕，黄雪敏，李大亮，岑树坤，蒋林青. 局部枸橼酸抗凝在重症急性肾损伤患者连续性肾脏替代治疗中的应用分析. 实用中西医结合临床. 2022(17): 31-33+37 . 百度学术
12.	金源源，诸炳骅，费雪洁，王倩. 局部枸橼酸抗凝在肝衰竭患者连续性肾脏替代治疗中的应用. 临床肝胆病杂志. 2021(01): 200-203 . 本站查看
13.	胡新，毛智，周飞虎. 枸橼酸抗凝在重症患者连续血液净化中的应用进展. 武警医学. 2021(01): 78-81 . 百度学术
14.	杨向莎，杨福燕，张瑞霞，张军. 改良式枸橼酸钠与低分子量肝素在急性肾损伤CRRT中的抗凝效果比较. 临床医学研究与实践. 2021(20): 46-49 . 百度学术
15.	冉梦晓，陈辉，郑浩天. 枸橼酸局部抗凝技术在血液透析中的应用进展. 中国医药. 2021(07): 1113-1116 . 百度学术
16.	杨妮娜，李之诉，杨禄，陈王峰. RCA-CRRT治疗中滤器后离子钙与体内离子钙的相关性. 现代实用医学. 2021(08): 993-995 . 百度学术
17.	焦清海，郑丽环，张雪梅，王征，杜菲，陈亮. 局部枸橼酸抗凝在危重症患者持续肾脏替代疗法中的临床应用. 河北医科大学学报. 2021(10): 1144-1148 . 百度学术
18.	王敬文. 枸橼酸与肝素抗凝对重症血液净化患者临床指标和安全性的影响比较. 中外医学研究. 2021(32): 40-43 . 百度学术
19.	冯菁，李和文，张兴凯，王建华，张作鹏，郭燕蓉，任航奇. 肝衰竭患者行局部枸橼酸抗凝连续性肾脏替代治疗时发生枸橼酸蓄积的影响因素分析. 临床和实验医学杂志. 2021(22): 2402-2406 . 百度学术
20.	李杨，由丽丽. 连续性肾脏替代治疗脑出血合并急性肾损伤患者中应用局部枸橼酸抗凝治疗的有效性及安全性. 中国医药指南. 2020(36): 89-90 . 百度学术